[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"herpangina\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:herpangina":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100637880","phase-3-protective-efficacy--immunogenicity-and-safety-of-the-tetravalent-inactivated-enterovirus-vaccine-vero-cell-100637880",false,"NCT07611513","Protective Efficacy , Immunogenicity and Safety of the Tetravalent Inactivated Enterovirus Vaccine (Vero Cell).","Multicenter, Randomized, Double-blind, Placebo-Controlled Phase IIIa Clinical Trial on the Protective Efficacy , Immunogenicity and Safety of the Tetravalent Inactivated Enterovirus Vaccine (Vero Cell) in Children Aged 6 to 71 Months.","Inclusion Criteria:\n\n1. Healthy children aged 6 to 71 months.\n2. Guardians who can understand and voluntarily sign the informed consent form\n3. Willing and able to comply with all visit schedules, sample collection, vaccinations, and other trial procedures。\n4. Provide legal identification for the participant and their guardian\n\nExclusion Criteria:\n\n1. A known history of HFMD\u002FHA\n2. Uncontrolled chronic diseases or a history of severe illnesses, including but not limited to cardiovascular diseases, blood disorders, liver or kidney diseases, digestive system diseases, respiratory system diseases, malignant tumors, or a history of major functional organ transplantation.\n3. Autoimmune diseases, immunodeficiency diseases (including but not limited to systemic lupus erythematosus, ankylosing spondylitis, autoimmune thyroid diseases, asplenia, functional asplenia, and HIV infection).\n4. Abnormal coagulation function (such as coagulation factor deficiencies,and platelet abnormalities).\n5. Suffering from\u002Fhaving a history of severe neurological diseases (epilepsy, convulsions, or seizures \\[excluding a history of febrile seizures\\]) ,psychiatric disorders, or a family history of psychiatric disorders\n6. Various acute diseases or exacerbations of chronic diseases within the last 3 days.\n7. Having been vaccinated with a vaccine containing any of the components EV71, CA16, CA10, CA6.\n8. Having received ≥14 days of immunosuppressive or other immunomodulatory treatment (prednisone ≥2mg\u002Fkg\u002Fday, or its equivalent; local or inhaled corticosteroids excluded) within the past 6 months, or cytotoxic treatment, or planning to receive such treatment during the trial.\n9. Having received immunoglobulin or other blood products(excluding hepatitis B immunoglobulin) within the past 6 months, or planning to receive such treatment during the trial.\n10. Having received other investigational drugs or vaccines within the past 30 days, or planning to receive such drugs or vaccines during the trial.\n11. Having received live attenuated vaccines or nucleic acid vaccines within the past 14 days, or subunit or inactivated vaccines within the past 7 days.\n12. Known allergy to any component of the investigational vaccine (inactivated EV71 virus, inactivated CA16 virus, , inactivated CA10 virus,, inactivated CA6 virus,aluminum hydroxide, sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, injectable water).\n13. On the day of planned vaccination with the investigational vaccine, having an axillary temperature ≥37.3°C before vaccination, or other vital sign measurements outside the normal range,or the physical examination is not qualified.\n14. According to the investigator's judgment, participants have any other factors that make them unsuitable for participation in the clinical trial.",true,"ALL","6 Months","71 Months",{"count":21,"type":22},6000,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","This multicenter, randomized, double-blind, placebo-controlled phase IIIa clinical trial aims to evaluate the protective efficacy , immunogenicity and safety of the Tetravalent Inactivated Enterovirus Vaccine (Vero Cell) in Children aged 6 to 71 months.\n\nParticipants will be randomly assigned in a 1:1 ratio to the trial group and the placebo group, receiving two doses of experimental vaccine or placebo , with a one-month interval between the two doses.",[28,29],"Hand, Foot, and Mouth Disease(HFMD)","Herpangina",[31,29,32,33,34,35],"Hand, Foot, and Mouth Disease (HFMD)","phase IIIa","immunogenicity","safety","protective efficacy","NOT_YET_RECRUITING","2026-05-22",{"date":39,"type":40},"2026-05-28","ACTUAL",{"date":42,"type":22},"2026-05",{"date":44,"type":22},"2028-09",{"name":46,"class":47},"Sinovac Biotech Co., Ltd","INDUSTRY",5,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":81},"100536331","surveillance-of-hfmd-in-pediatric-outpatients-100536331","NCT06263439","Surveillance of HFMD in Pediatric Outpatients","Prospective Clinico-virological Surveillance of Diseases Foot-hand-mouth\u002FHerpangina Associated With Enteroviruses in Pediatric Outpatients","PMB","Inclusion Criteria:\n\n* Children aged 0 to 10 years presenting with HFMD or herpangina\n\nExclusion Criteria:\n\n* Refusal to participate by holders of parental authority\n* Refusal to participate for children over 3 years of age","10 Years",{"count":59,"type":22},3000,"OBSERVATIONAL","The aims of this prospective multicentric study is to determine the types of enteroviruses (EVs) responsible for hand, foot and mouth disease (HFMD) or herpangina in children seen within an ambulatory setting :\n\n* to detect an EV-A71 epidemic or another type associated with atypical forms of the disease at an early stage\n* to describe and compare the epidemiological, demographic, clinical and virological characteristics of these infections between the different types of EV.",[63,29,64],"Hand, Foot and Mouth Disease","Enterovirus Infections",[66,67,68,29,69],"Hand, foot and mouth disease","Enterovirus A71","Coxsackievirus A6","Primary care in paediatrics","RECRUITING","2024-02-15",{"date":73,"type":40},"2024-02-16",{"date":75,"type":40},"2023-06-20",{"date":77,"type":22},"2028-06-20",{"name":79,"class":80},"University Hospital, Clermont-Ferrand","OTHER",1]